Jonathan M. Cohen - 17 Feb 2026 Form 3 Insider Report for 20/20 Biolabs, Inc.

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: AIDX on Nasdaq
Reported as of: 17 Feb 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 19 Feb 2026, 17:52:33 UTC
Next SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Cohen

Key filing fact

Jonathan M. Cohen filed Form 3 for 20/20 Biolabs, Inc. on 19 Feb 2026.

Key facts

This page summarizes Jonathan M. Cohen's Form 3 filing for 20/20 Biolabs, Inc..
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Feb 2026, 17:52.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002111543 Primary reporting owner

Cohen Jonathan M

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG
Signature: /s/ Jonathan Cohen
Signature date: 19 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,366,400
Date: 17 Feb 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 388,000
Exercise price: $1.74
Footnotes: F1

No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $2.55
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 388,000 shares of common stock, with 194,000 shares vested on the date of the grant and the remaining shares vested in equal monthly installments over the following 24 months.

Footnote F2

On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 125,000 shares of common stock, with 31,250 shares vesting on the date of grant and the remaining shares vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.